Latest news
Boston Scientific Launches FARADIGM Trial for Next-Gen PFA Device as EP Business Faces Pressure - Medical Device and Diagnostic industryMedical Device and Diagnostic industry · Mon, 03 Aug 2026 13:11:23 GMTBoston Scientific posts Q2 2026 revenue $5.442B, adjusted EPS $0.86 - TradingViewTradingView · Wed, 29 Jul 2026 10:43:00 GMTBoston Scientific initiates FARADIGM trial to evaluate Faraflex ‘map-and-ablate’ catheter - Cardiac Rhythm NewsCardiac Rhythm News · Mon, 27 Jul 2026 08:03:04 GMT